A previous meta-analysis demonstrated that the presence of KRAS mutations was a negative prognostic factor for the overall survival of patients with lung cancer, but a more recent study showed that only the presence of KRAS mutations in exon 2 had a predictive value in adenocarcinoma (ADC) patients [27, 29]. This evidence concerns the gene KRAS and lung cancer.